Position in AZN
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$304,632,320
New position
Shares Held
1,544,632
first reported quarter
Ownership
0.100%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 98.2736988486578.ToString("F0")%
Shared 0.ToString("F0")%
None 1.7263011513421966.ToString("F0")%
Derivatives in AZN
reported options exposure · as of Mar 31, 2026CallValue
$19,327,560
CallShares
98,000
PutValue
$2,366,640
PutShares
12,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026WELLS FARGO & COMPANY/MN holds $16,837,469,445 across 20 Drug Manufacturers - General names. AZN ranks #9 (1.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
16,925,454 | $4,137,257,974 | |
| 2 | LLY |
ELI LILLY & Co
|
4,405,844 | $4,052,363,133 | |
| 3 | AMGN |
Amgen Inc
|
7,088,010 | $2,493,916,315 | |
| 4 | ABBV |
AbbVie Inc.
|
8,909,597 | $1,937,748,249 | |
| 5 | MRK |
Merck & Co., Inc.
|
11,446,845 | $1,376,940,982 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
6,628,441 | $923,805,819 | |
| 7 | PFE |
Pfizer Inc
|
19,533,309 | $548,495,315 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
5,946,447 | $360,652,008 |
All Filings in AZN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $304,632,320 | 1,544,632 | Shares | Defined | 2026-05-11 | |
| 2026-03-31 | $2,366,640 | 12,000 | Put | Defined | 2026-05-11 | |
| 2026-03-31 | $19,327,560 | 98,000 | Call | Defined | 2026-05-11 | |
| No filing history on record for this holder in this stock. | ||||||